Presentation of SNF472 Data at the American Society of Nephrology Kidney Week 2015
Laboratoris Sanifit, a clinical stage biopharmaceutical company focused on the discovery and development of a novel therapeutic candidate, SNF472, for the treatment of calciphylaxis and vascular calcification in ESRD patients, today reported that they will present preclinical and interim clinical data at the American Society of Nephrology (ASN) Kidney Week 2015, being held in San Diego, CA on November 3-8, 2015.
Preliminary data from an ongoing Phase 1 clinical study of SNF472 in healthy volunteers and ESRD patients on haemodialysis, including effects on safety, pharmacodynamics, and tolerability, will be presented on Friday, November 6, 2015. Additionally, data from preclinical studies will be presented on Saturday, November 7, 2015.
Friday, November 6, 2015, from 4:30 PM – 6:30 PM (PST)
- “First experience with a novel inhibitor of vascular calcification (SNF472) in healthy volunteers and ESRD patients on hemodialysis” (clinical oral presentation (FR-OR030))
Saturday, November 7, 2015 from 10:00 AM – 12:00 PM (PST)
- “SNF472 inhibits cardiovascular calcification in uremic rats” (preclinical poster presentation (SA-PO595))